Compare Abeona Therapeutics Inc (ABEO) vs Newmont Corporation (NEM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Newmont Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Newmont Corporation trades at $93.23 (market cap $101.48B). The key difference: Newmont Corporation is far larger — about 271.8× Abeona Therapeutics Inc's market cap, and Newmont Corporation pays a 1.09% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | NEM | |
|---|---|---|
Market Cap | $373.32M | $101.48B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $131.95 |
52-Week Low | $4.17 | $57.35 |
Enterprise Value | $228.22M | $98.23B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Newmont Corporation (NEM) trades at $95.06, down 2.04% over 24 hours amid a bearish technical signal. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $2.90 versus $2.07 expected, revenue growth to $22.67 billion in 2025, and robust cash flow of $10.33 billion from operations. Analyst consensus is bullish with a $144.00 price target and 75% buy ratings, though recent gold price volatility has pressured shares.
The outlook remains positive due to low valuation multiples (P/E 12.74, EV/EBITDA 6.27) and record free cash flow, but risks include gold market fluctuations and execution of expansion projects. The stock presents a value opportunity for long-term investors, supported by a strong balance sheet and dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
